Pharmacokinetics of hERG Channel Blocking Voacangine in Wistar Rats Applying a Validated LC-ESI-MS/MS Method^[*]

Abstract

Herbal preparations from Voacanga africana are used in West and Central African folk medicine and are also becoming increasingly popular as a legal high in Europe. Recently, the main alkaloid voacangine was found to be a potent human ether-à-go-go-related gene channel blocker in vitro. Blockage of this channel might imply possible cardiotoxicity. Therefore, the aim of this study was to characterise voacangine in vivo to assess its pharmacokinetics and to estimate if further studies to investigate its cardiotoxic risk are required. Male Wistar rats received different doses of voacangine as a pure compound and as a hydro-ethanolic extract of V. africana root bark with a quantified amount of 9.71 % voacangine. For the obtained data, a simultaneous population pharmacokinetics model was successfully developed, comprising a two-compartment model for i. v. dosing and a one-compartmental model with two first-order absorption rates for oral dosing. The absolute bioavailability of voacangine was determined to be 11–13 %. Model analysis showed significant differences in the first absorption rate constant for voacangine administered as a pure compound and voacangine from the extract of V. africana. Taking into account the obtained low bioavailability of voacangine, its cardiotoxic risk might be neglectable in healthy consumers, but may have a serious impact in light of drug/drug interactions and impaired health conditions.

Key words

Voacanga africana - Apocynaceae - voacangine - hERG channel - in vivo - population pharmacokinetics - Wistar rat plasma

^* Dedicated to Professor Dr. Dr. h. c. mult. Kurt Hostettmann.

^** These authors contributed equally to this work.

• References

• 1 Ameyaw Y, Duker-Eshun G. The alkaloid content of the ethno-plant organs of three antimalarial medicinal plants species in the eastern region of Ghana. Int J Chem Sci 2009; 7: 48-58
• 2 Tona L, Kambu K, Mesia K, Cimanga K, Apers S, De Bruyne T, Pieters L, Totté J, Vlietinck A. Biological screening of traditional preparations from some medicinal plants used as antidiarrhoeal in Kinshasa, Congo. Phytomedicine 1999; 6: 59-66
• 3 Ndenecho EN. Herbalism and resources for the development of ethnopharmacology in Mount Cameroon region. Afr J Pharm Pharmacol 2009; 3: 78-86
• 4 Currais A, Chiruta C, Goujon-Svrzic M, Costa G, Santos T, Batista MT, Paiva J, do Ceu Madureira M, Maher P. Screening and identification of neuroprotective compounds relevant to Alzheimerʼs disease from medicinal plants of S. Tomé e Príncipe. J Ethnopharmacol 2014; 155: 830-840
• 5 Omodamiro OD, Nwankwo CI. The effect of Voacanga africana leaves extract on serum lipid profile and haematological parameters on albino wistar rats. Eur J Exp Biol 2013; 3: 140-148
• 6 Kikura-Hanajiri R, Maruyama T, Miyashita A, Goda Y. [Chemical and DNA analyses for the products of a psychoactive plant, Voacanga africana]. J Pharm Soc Jpn 2009; 129: 975-982
• 7 Bisset NG. Phytochemistry and pharmacology of Voacanga species. In: Leeuwenberg AJM, editor Series of revisions of Apocynaceae 15. Wageningen, Netherlands: Wageningen Agricultural University Papers; 1985: 81-113
• 8 Brown TK. Ibogaine in the treatment of substance dependence. Curr Drug Abuse Rev 2013; 6: 3-16
• 9 Alper KR, Stajić M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci 2012; 57: 398-412
• 10 Kim Y, Jung HJ, Kwon HJ. A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo . Biochem Biophys Res Commun 2012; 417: 330-334
• 11 Prakash Chaturvedula VS, Sprague S, Schilling JK, Kingston DG. New cytotoxic indole alkaloids from Tabernaemontana calcarea from the Madagascar rainforest. J Nat Prod 2003; 66: 528-531
• 12 Zhan ZJ, Yu Q, Wang ZL, Shan WG. Indole alkaloids from Ervatamia hainanensis with potent acetylcholinesterase inhibition activities. Bioorg Med Chem Lett 2010; 20: 6185-6187
• 13 Terada Y, Horie S, Takayama H, Uchida K, Tominaga M, Watanabe T. Activation and inhibition of thermosensitive TRP channels by voacangine, an alkaloid present in Voacanga africana, an African tree. J Nat Prod 2014; 77: 285-297
• 14 Kratz JM, Schuster D, Edtbauer M, Saxena P, Mair CE, Kirchebner J, Matuszczak B, Baburin I, Hering S, Rollinger JM. Experimentally validated hERG pharmacophore models as cardiotoxicity prediction tools. J Chem Inf Model 2014; 54: 2887-2901
• 15 Raschi E, Vasina V, Poluzzi E, De Ponti F. The hERG K+ channel: target and antitarget strategies in drug development. Pharmacol Res 2008; 57: 181-195
• 16 Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature 2006; 440: 463-469
• 17 Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y, Hill AP. hERG K(+) channels: structure, function, and clinical significance. Physiol Rev 2012; 92: 1393-1478
• 18 Koenig X, Kovar M, Boehm S, Sandtner W, Hilber K. Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk. Addict Biol 2014; 19: 237-239
• 19 Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules 2015; 20: 2208-2228
• 20 FDA. Guidance for industry. Bioanalytical method validation. Available at. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070107.pdf Accessed May 1, 2016
• 21 Smith DA, Di L, Kerns EH. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 2010; 9: 929-939
• 22 Petricoul O, Cosson V, Fuseau E, Marchand M. Population models for drug absorption and enterohepatic recycling. In: Ette EI, Williams PJ, editors Pharmacometrics: the science of quantitative pharmacology. Hoboken: John Wiley & Sons, Inc.; 2007
• 23 Davies NM, Takemoto JK, Brocks DR, Yáñez JA. Multiple peaking phenomena in pharmacokinetic disposition. Clin Pharmacokinet 2010; 49: 351-377
• 24 Owen JS, Fiedler-Kelly J. Introduction to Population Pharmacokinetic/Pharmacodynamics Analysis with nonlinear mixed Effects Models. New Jersey: John Wiley & Sons, Inc.; 2014
• 25 Hough LB, Bagal AA, Glick SD. Pharmacokinetic characterization of the indole alkaloid ibogaine in rats. Methods Find Exp Clin Pharmacol 2000; 22: 77-81
• 26 Jeffcoat AR, Cook CE, Hill JM, Coleman DP, Pollack GM. Disposition of [3 H] ibogaine in the rat. In: Harris LS, editor. Problems of drug dependence 1993, Vol. 2. Rockville, MD: National Institutes of Health; 1994. 141. 309
• 27 Maciulaitis R, Kontrimaviciute V, Bressolle FM, Briedis V. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Hum Exp Toxicol 2008; 27: 181-194
• 28 McIntyre TA, Han C, Xiang H, Bambal R, Davis CB. Differences in the total body clearance of lead compounds in the rat and mouse: impact on pharmacokinetic screening strategy. Xenobiotica 2008; 38: 605-619
• 29 Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095
• 30 Ward KW, Smith BR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. Drug Metab Dispos 2004; 32: 612-619
• 31 Li P, Zhao L. Developing early formulations: practice and perspective. Int J Pharm 2007; 341: 1-19
• 32 Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit – a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241-257
• 33 Beal S, Sheiner LB, Boeckmann A, Bauer RJ. Nonmemʼs Userʼs Guides. Dublin: Icon Development Solutions; 2013
• 34 Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol 2012; 1: e6
• 35 Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol 2013; 2: e50